Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03772340 · ClinicalTrials.gov registry record · Phase 2
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
A Phase 2 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT03772340 is a Phase 2 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 126 participants.
The verdict
NCT03772340, a Phase 2 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
Randomized, double-blind, placebo-controlled investigating the efficacy of tradipitant in the treatment of motion sickness.
Interventions
- DRUG Placebo
- DRUG Tradipitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2019-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03772340
The ClinicalTrials.gov registry entry for NCT03772340 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03772340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03772340 about?
NCT03772340 is a clinical study titled "Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness". Randomized, double-blind, placebo-controlled investigating the efficacy of tradipitant in the treatment of motion sickness.
What is the current status of trial NCT03772340?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2018-12-20. Estimated completion is 2019-06-27.
What interventions are being tested in trial NCT03772340?
The interventions under investigation include: Placebo (DRUG), Tradipitant (DRUG).
Who is sponsoring clinical trial NCT03772340?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.